Peter Forsberg, MD, and Robert M. Rifkin, MD, FACP, discussed the trials supporting use of BCMA-targeted agents for relapsed/refractory multiple myeloma.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Rifkin and Forsberg Review Trials of BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
Default sub title
minute read
by Targeted Oncology | August 23, 2022
